Analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT - Get Free Report) in a research note issued to investors on Thursday. The firm set a "hold" rating on the stock.
DBVT has been the subject of a number of other research reports. HC Wainwright boosted their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th. JMP Securities restated a "market outperform" rating and set a $10.00 target price on shares of DBV Technologies in a research report on Tuesday, December 10th.
Get Our Latest Analysis on DBVT
DBV Technologies Trading Up 10.4 %
Shares of DBVT traded up $0.36 during mid-day trading on Thursday, hitting $3.83. 1,228,280 shares of the company traded hands, compared to its average volume of 253,424. The business has a 50-day moving average of $3.29 and a 200 day moving average of $3.82. DBV Technologies has a one year low of $2.20 and a one year high of $9.50. The stock has a market capitalization of $78.78 million, a price-to-earnings ratio of -0.85 and a beta of 0.64.
About DBV Technologies
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Read More
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
